Hot Topics in Pediatric rhinosinusitis

Saturday, October 17, 2026

9:30 AM - 10:20 AM PT

Location: West Exhibit Hall A, Learning Zone 5

Moderator(s)

Jacqueline C. Alvarado, MD

Past President
Pan American Otolaryngology Association -HNS
ATLANTA, GA, United States

Panelist(s)

Jose L. Mayorga, MD, MSC, PHD

CHAIR PEDIATRIC OTOLARYNGOLOGY DEPARTMENT AND PROFESSOR OF THE RESIDENCY PROGRAM
NATIONAL INSTITUTE OF PEDIATRICS
Ciudad de Mexico, Distrito Federal, Mexico
Erika M. Celis, MD

Dr
Hospital Angeles CuliacanTorre De Consultorios (Consultorio 603)
Culiacan, Sinaloa, Sinaloa, Mexico

Disclosure(s):

Jacqueline C. Alvarado, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Jose L. Mayorga, MD, MSC, PHD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Participants will receive a practical, up‑to‑date overview of emerging issues shaping pediatric chronic rhinosinusitis care. The session will cover evolving disease mechanisms, pediatric‑specific inflammatory patterns, and how comorbidity‑driven phenotyping—such as adenoid disease, allergic rhinitis/asthma overlap, and pediatric nasal polyposis—guides evaluation and treatment. Faculty will review current biomarker insights, contemporary medical and procedural management pathways, and the evolving role of biologic therapy, with attention to patient selection, multidisciplinary coordination, and evidence limitations.

Learning Objectives:

Upon completion, participants will be able to describe emerging mechanisms and pediatric-specific inflammatory patterns that influence the development and persistence of chronic rhinosinusitis in children.
Upon completion, participants will be able to identify how comorbidity‑driven phenotyping—such as adenoid disease, allergic inflammation, asthma overlap, and pediatric nasal polyposis—guides diagnostic evaluation and treatment selection.
Upon completion, participants will be able to outline current medical, procedural, and biologic treatment pathways for pediatric chronic rhinosinusitis, including indications, patient selection, and evidence‑based decision points.